Division of Neurosciences and Mental Health and MRC Clinical Sciences Centre, Faculty of Medicine, Hammersmith Hospital, Imperial College, London, UK.
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S33-7. doi: 10.1016/S1353-8020(09)70832-6.
The most challenging issue when testing putative neuroprotective agents for Parkinson's disease (PD) in clinical trials is the assessment of the effect of the treatment on the neurodegenerative process. By measuring changes in symptoms severity, clinical rating scales represent an important tool to rate the progression of the disease. However, the rating of clinical symptoms is dependent on the examiner and the neuroprotective effect can be masked by the symptomatic effect of the therapy. 18F-dopa PET and 123I-beta-CIT SPECT have been shown to be able to monitor the progressive loss of presynaptic nigrostriatal projections in PD and have been used as surrogate biomarkers of disease in several recent clinical trials. In this article the value of imaging as a biomarker for testing neuroprotective agents in PD is reviewed.
在临床试验中测试疑似帕金森病 (PD) 的神经保护剂时，最具挑战性的问题是评估治疗对神经退行性过程的影响。通过测量症状严重程度的变化，临床评分量表是评估疾病进展的重要工具。然而，临床症状的评分依赖于检查者，并且治疗的症状效应可能掩盖神经保护作用。18F-多巴 PET 和 123I-β-CIT SPECT 已被证明能够监测 PD 中突触前黑质纹状体投射的进行性丧失，并已在最近的几项临床试验中被用作疾病的替代生物标志物。本文回顾了影像学作为 PD 神经保护剂测试的生物标志物的价值。
